Evidence map›Paper›PMID 32929842›Full record

ArticleEMBO reports2020

TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8

Shuangqi Li, Jiuxing Feng, Feizhen Wu, Jiabin Cai, Xinyu Zhang, Haikun Wang, Irfete S Fetahu, Isabella Iwanicki, Dingailu Ma, Tao Hu and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Clonal Hematopoiesis of Indeterminate Potential Influences Breast Cancer Outcomes in a Genotype-Specific Manner.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Epitranscriptomics Regulation of CD70, CD80, and TIGIT in Cancer Immunity.International journal of molecular sciences · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Shuangqi Li *Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-1128-3865
Jiuxing Feng *Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Feizhen Wu *Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID 0000-0002-1265-9887
Jiabin CaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinyu ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Haikun WangKey Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Irfete S FetahuDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0468-7458
Isabella IwanickiDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dingailu MaKey Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-9875-844X
Tao HuKey Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Hang LiuKey Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Bingjie WangKey Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Guoming ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-3817-9117
Li TanKey Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-5961-0450
Yujiang Geno ShiDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9490-7081
Fudan University · CNBrigham and Women's Hospital · USInstitut Pasteur of Shanghai · CN

Funding

National Natural Science Foundation of China (NSF) 31871291National Natural Science Foundation of China (NSF) 81672785National Natural Science Foundation of China (NSF) 81972232Science and Technology Commission of Shanghai Municipality (STCSM) 2017SHZDZX01
6 · The paper itself

Abstract

The host immune response is a fundamental mechanism for attenuating cancer progression. Here we report a role for the DNA demethylase and tumor suppressor TET2 in host anti-tumor immunity. Deletion of Tet2 in mice elevates IL-6 levels upon tumor challenge. Elevated IL-6 stimulates immunosuppressive granulocytic myeloid-derived suppressor cells (G-MDSCs), which in turn reduce CD8

Indexed as

Myeloid-Derived Suppressor CellsNeoplasmsAdaptive ImmunityAnimalsCD8-Positive T-LymphocytesCell CountDioxygenasesDNA-Binding ProteinsMiceProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTet2 protein, mouseanti-tumor immune responsegranulocytic myeloid-derived suppressor cellsIL-6syngeneic tumorTet2

Identifiers

PMID32929842
PMCPMC7534639
OpenAlexW3086904810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.